medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2024-29-56-60medalphabet-4048Research ArticleСтатьиКардиоваскулярная патология при спондилоартритах (обзор литературы)Cardiovascular diseases in spondyloarthritis (literature review)https://orcid.org/0000-0001-6392-8461КоройП. В.KoroyP. V.

Павел Владимирович Корой, д. м. н., проф., проф. кафедры

кафедра госпитальной терапии

Ставрополь

Pavel V. Koroy, DM Sci (habil.), porofessor, professor at Dept

Dept of Hospital Therapy

Stavropol

paule75@yandex.ruhttps://orcid.org/0000-0003-4510-3604ГладкихН. Н.GladkikhN. N.

Наталья Николаевна Гладких, д. м. н., проф., проф. кафедры

кафедра госпитальной терапии

Ставрополь

Natalia N. Gladkikh, DM Sci (habil.), professor

Dept of Hospital Therapy

Stavropol

ngladkih@mail.ruhttps://orcid.org/0000-0002-5727-1640ЯгодаА. В.YagodaA. V.

Александр Валентинович Ягода, д. м. н., проф., зав. кафедрой

кафедра госпитальной терапии

Ставрополь

Alexander V. Yagoda, DM Sci (habil.), professor, head of Dept

Dept of Hospital Therapy

Stavropol

alexander.yagoda@gmail.comhttps://orcid.org/0009-0006-7244-3507ДудовТ. Р.DudovT. R.

Темирлан Русланович Дудов, ассистент

кафедра госпитальной терапии

Ставрополь

Temirlan R. Dudov, assistant

Dept of Hospital Therapy

Stavropol

timur222123@mail.ruhttps://orcid.org/0009-0004-4747-2715КозаковаС. А.KozakovaS. A.

Светлана Александровна Козакова, к. м. н., доцент

кафедра госпитальной терапии

Ставрополь

Svetlana A. Kozakova, PhD Med, associate professor

Dept of Hospital Therapy

Stavropol

kozakova.76@mail.ruФГБОУ ВО «Ставропольский государственный медицинский университет» Минздрава РоссииРоссияStavropol State Medical UniversityRussian Federation202412122024029Ревматология в общей врачебной практике (2)5660Copyright © Корой П.В., Гладких Н.Н., Ягода А.В., Дудов Т.Р., Козакова С.А., 20242024Корой П.В., Гладких Н.Н., Ягода А.В., Дудов Т.Р., Козакова С.А.Koroy P.V., Gladkikh N.N., Yagoda A.V., Dudov T.R., Kozakova S.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/4048

   Спондилоартриты – группа заболеваний с поражением осевого скелета и крестцово-подвздошных суставов, включающая аксиальный спондилоартрит, или анкилозирующий спондилит, и периферический спондилоартрит. Спондилоартриты ассоциированы с увеличением сердечно-сосудистой заболеваемости и смертности, которая может быть результатом кардиальных проявлений болезни или обусловлена ускоренным развитием атеросклероза. Сочетание двух патологий способствует более тяжелому течению заболеваний и негативно влияет на результаты терапии, что свидетельствует об актуальности этой междисциплинарной проблемы. В обзоре освещены данные о сердечно-сосудистой заболеваемости и смертности при спондилоартритах, встречаемости различных факторов риска. Приведены данные о взаимосвязи кардиоваскулярной патологии с активностью и функциональными нарушениями при спондилоартритах.

   Spondyloarthritis is a group of diseases involving the axial skeleton and sacroiliac joints, including axial spondyloarthritis or ankylosing spondylitis and peripheral spondyloarthritis. Spondyloarthritis is associated with an increase in cardiovascular morbidity and mortality, which may be the result of cardiac manifestations of disease or due to the accelerated development of atherosclerosis. The combination of two pathologies contributes to a more severe course of diseases and negatively affects the results of therapy, which indicates the relevance of this interdisciplinary problem. The review highlights data on cardiovascular morbidity and mortality in spondyloarthritis, the occurrence of various risk factors. The data on the relationship of cardiovascular pathology with activity and functional disorders in spondyloarthritis are presented.

спондилоартритыанкилозирующий спондилитаксиальный спондилоартритпериферический спондилоартритпсориатический артритсердечно-сосудистые заболеванияфакторы кардиоваскулярного рискаspondyloarthritisankylosing spondylitisaxial spondyloarthritisperipheral spondyloarthritispsoriatic arthritiscardiovascular diseasescardiovascular risk factorsReferencesBosch P., Zhao S. S., Nikiphorou E. The association between comorbidities and disease activity in spondyloarthritis – a narrative review. Best Pract. Res. Clin. Rheumatol. 2023; 37 (3): 101857. doi: 10.1016/j.berh.2023.101857Bosch P., Zhao S. S., Nikiphorou E. The association between comorbidities and disease activity in spondyloarthritis – a narrative review. Best Pract. Res. Clin. Rheumatol. 2023; 37 (3): 101857. doi: 10.1016/j.berh.2023.101857Dey M., Nagy G., Nikiphorou E. Comorbidities or extra-articular manifestations: time to reconsider the terminology? Rheumatology. 2022; 61 (10): 3881e3. doi: 10.1093/rheumatology/keac134Dey M., Nagy G., Nikiphorou E. Comorbidities or extra-articular manifestations: time to reconsider the terminology? Rheumatology. 2022; 61 (10): 3881e3. doi: 10.1093/rheumatology/keac134Gupta S., Syrimi Z., Hughes D. M. et al. Comorbidities in psoriatic arthritis : a systematic review and meta-analysis. Rheumatol. Int. 2021; 41 (2): 275e84. doi: 10.1007/s00296-020-04775-2Gupta S., Syrimi Z., Hughes D. M. et al. Comorbidities in psoriatic arthritis : a systematic review and meta-analysis. Rheumatol. Int. 2021; 41 (2): 275e84. doi: 10.1007/s00296-020-04775-2Zhao S. S., Robertson S., Reich T. et al. Prevalence and impact of comorbidities in axial spondyloarthritis : systematic review and meta-analysis. Rheumatology. 2020; 59: iv47e57. doi: 10.1093/rheumatology/keaa246Zhao S. S., Robertson S., Reich T. et al. Prevalence and impact of comorbidities in axial spondyloarthritis : systematic review and meta-analysis. Rheumatology. 2020; 59: iv47e57. doi: 10.1093/rheumatology/keaa246Bhattad P., Kulkarni M., Patel P. D. et al. Cardiovascular morbidity in ankylosing spondylitis: a focus on inflammatory cardiac disease. Cureus. 2022; 14 (6): e25633. doi: 10.7759/cureus.25633Bhattad P., Kulkarni M., Patel P. D. et al. Cardiovascular morbidity in ankylosing spondylitis: a focus on inflammatory cardiac disease. Cureus. 2022; 14 (6): e25633. doi: 10.7759/cureus.25633Kim J. H., Choi I. A. Cardiovascular morbidity, and mortality in patients with spondylarthritis: a meta-analysis. Int. J. Rheum. Dis. 2020; 24 (4): 477–486. doi: 10.1111/1756-185X.13970Kim J. H., Choi I. A. Cardiovascular morbidity, and mortality in patients with spondylarthritis: a meta-analysis. Int. J. Rheum. Dis. 2020; 24 (4): 477–486. doi: 10.1111/1756-185X.13970Ягода А. В., Гладких Н. Н. Эндокард и клапаны сердца при системных ревматических болезнях. Ставрополь: Изд-во СтГМУ; 2021: 384.Yagoda A. V., Gladkih N. N. Endocardium and heart valves in systemic rheumatic diseases. Stavropol: StGMU; 2021: 384. (In Russ.).Lai Y., Zhang Y., Mo S. et al. Prevalence of comorbidities and risk factors in spondyloarthritis: results of a cross-sectional study. Ann. Rheum. Dis. 2022; 81: e43. doi: 10.1136/annrheumdis-2020-217313Lai Y., Zhang Y., Mo S. et al. Prevalence of comorbidities and risk factors in spondyloarthritis: results of a cross-sectional study. Ann. Rheum. Dis. 2022; 81: e43. doi: 10.1136/annrheumdis-2020-217313Redeker I., Callhoff J., Hoffmann F. et al. The prevalence and impact of comorbidities on patients with axial spondyloarthritis: results from a nationwide population-based study. Arthritis Res. Ther. 2020; 22 (1): 210. doi: 10.1186/s13075-020-02301-0Redeker I., Callhoff J., Hoffmann F. et al. The prevalence and impact of comorbidities on patients with axial spondyloarthritis: results from a nationwide population-based study. Arthritis Res. Ther. 2020; 22 (1): 210. doi: 10.1186/s13075-020-02301-0Gökşenoğlu G., Buğdaycı D., Paker N. et al. The prevalence of comorbidity and predictors in ankylosing spondylitis. Turk. J. Phys. Med. Rehabil. 2019; 65 (2): 132–138. doi: 10.5606/tftrd.2019.2822Gökşenoğlu G., Buğdaycı D., Paker N. et al. The prevalence of comorbidity and predictors in ankylosing spondylitis. Turk. J. Phys. Med. Rehabil. 2019; 65 (2): 132–138. doi: 10.5606/tftrd.2019.2822Годзенко А. А., Корсакова Ю. О., Румянцева О. А. и др. Прогрессирование патологии аорты и клапанов сердца у больных анкилозирующим спондилитом. Научно-практическая ревматология. 2017; 55 (5): 509–513. doi: 10.14412/1995-4484-2017-509-513Godzenko A. A., Korsakova Yu.O., Rumyantseva O. A. et al. Progression of aortic and valvular heart diseases in patients with ankylosing spondylitis. Rheumatology Science and Practice. 2017; 55 (5): 509–513. (In Russ.). doi: 10.14412/1995-4484-2017-509-513Longo B., Kirchner L. A., Simioni J. et al. Electrocardiographic changes in spondyloarthritis and use of anti-TNF-α drugs: a retrospective study with 100 patients. Einstein (Sao Paulo). 2019; 17: eAO4539. doi: 10.31744/einstein_journal/2019AO4539Longo B., Kirchner L. A., Simioni J. et al. Electrocardiographic changes in spondyloarthritis and use of anti-TNF-α drugs: a retrospective study with 100 patients. Einstein (Sao Paulo). 2019; 17: eAO4539. doi: 10.31744/einstein_journal/2019AO4539Bengtsson K., Klingberg E., Deminger A. et al. Cardiac conduction disturbances in patients with ankylosing spondylitis: results from a 5-year follow-up cohort study. RMD Open. 2019; 5: e001053. doi: 10.1136/rmdopen-2019-001053Bengtsson K., Klingberg E., Deminger A. et al. Cardiac conduction disturbances in patients with ankylosing spondylitis: results from a 5-year follow-up cohort study. RMD Open. 2019; 5: e001053. doi: 10.1136/rmdopen-2019-001053Сay H. F., Alkan Melikoğlu M., Yurdakul F. G. et al. Real-life data on the comorbidities in spondyloarthritis from our multicenter nationwide registry: BioStar. Arch. Rheumatol. 2023; 38 (3): 333–346. doi: 10.46497/ArchRheumatol.2023.9793Сay H. F., Alkan Melikoğlu M., Yurdakul F. G. et al. Real-life data on the comorbidities in spondyloarthritis from our multicenter nationwide registry: BioStar. Arch. Rheumatol. 2023; 38 (3): 333–346. doi: 10.46497/ArchRheumatol.2023.9793Llop M., Gratacуs J., Moreno M. et al. Sex differential impact of comorbidities in spondyloarthritis: data from COMOSPA study. RMD Open. 2024; 10: e003776. doi: 10.1136/rmdopen-2023-003776Llop M., Gratacуs J., Moreno M. et al. Sex differential impact of comorbidities in spondyloarthritis: data from COMOSPA study. RMD Open. 2024; 10: e003776. doi: 10.1136/rmdopen-2023-003776Bengtsson K., Forsblad-d’Elia H., Lie E. et al. Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. Arthritis Res. Ther. 2017; 19: 102. doi: 10.1186/s13075-017-1315-zBengtsson K., Forsblad-d’Elia H., Lie E. et al. Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. Arthritis Res. Ther. 2017; 19: 102. doi: 10.1186/s13075-017-1315-zEriksson J. K., Jacobsson L., Bengtsson K. et al. Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis? Ann. Rheum. Dis. 2017; 76 (2): 364–370. doi: 10.1136/annrheumdis-2016-209315Eriksson J. K., Jacobsson L., Bengtsson K. et al. Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis? Ann. Rheum. Dis. 2017; 76 (2): 364–370. doi: 10.1136/annrheumdis-2016-209315Саидов Ё. У., Одилзода И. Ё., Хасанзода С. М. и др. Распространенность традиционных факторов риска развития сердечно-сосудистых осложнений у пациентов с ревматоидным и псориатическим артритом. Научно-практическая ревматология. 2020; 58 (2): 165–170. doi: 10.14412/1995-4484-2020-165-170Saidov Yo.U., Odilzoda I. Yo., Khasanzoda S. M. et al. The prevalence of traditional cardiovascular risk factors in patients with rheumatoid and in those with psoriatic arthritis. Rheumatology Science and Practice. 2020; 58 (2): 165–170. (In Russ.). doi: 10.14412/1995-4484-2020-165-170Moltó A., Nikiphorou E. Comorbidities in spondyloarthritis. Front. Med. 2018; 5: 62. doi: 10.3389/fmed.2018.00062Moltó A., Nikiphorou E. Comorbidities in spondyloarthritis. Front. Med. 2018; 5: 62. doi: 10.3389/fmed.2018.00062Rueda-Gotor J., Llorca J., Corrales A. et al. Carotid ultrasound in the cardiovascular risk stratification of patients with ankylosing spondylitis: results of a population-based study. Clin. Exp. Rheumatol. 2016; 34: 885–892.Rueda-Gotor J., Llorca J., Corrales A. et al. Carotid ultrasound in the cardiovascular risk stratification of patients with ankylosing spondylitis: results of a population-based study. Clin. Exp. Rheumatol. 2016; 34: 885–892.López-Medina C., Molto A. Comorbidity management in spondyloarthritis. RMD Open. 2020; 6: e001135. doi: 10.1136/rmdopen-2019-001135López-Medina C., Molto A. Comorbidity management in spondyloarthritis. RMD Open. 2020; 6: e001135. doi: 10.1136/rmdopen-2019-001135Arévalo M., López-Medina C., Moreno Martinez-Losa M. et al. Role of HLA-B 27 in the comorbidities observed in axial spondyloarthritis: data from COMOSPA. Joint Bone Spine. 2020; 87 (5): 445–448. doi: 10.1016/j.jbspin.2020.03.012Arévalo M., López-Medina C., Moreno Martinez-Losa M. et al. Role of HLA-B 27 in the comorbidities observed in axial spondyloarthritis: data from COMOSPA. Joint Bone Spine. 2020; 87 (5): 445–448. doi: 10.1016/j.jbspin.2020.03.012Walsh J. A., Song X., Kim G., Park Y. Evaluation of the comorbidity burden in patients with ankylosing spondylitis treated with tumour necrosis factor inhibitors using a large administrative claims data set. J. Pharm. Health. Serv. Res. 2018; 9 (2): 115–121. doi: 10.1111/jphs.12212Walsh J. A., Song X., Kim G., Park Y. Evaluation of the comorbidity burden in patients with ankylosing spondylitis treated with tumour necrosis factor inhibitors using a large administrative claims data set. J. Pharm. Health. Serv. Res. 2018; 9 (2): 115–121. doi: 10.1111/jphs.12212Exarchou S., Lie E., Lindström U. et al. Mortality in ankylosing spondylitis: results from a nationwide population-based study. Ann. Rheum. Dis. 2016; 75: 1466–1472. doi: 10.1136/annrheumdis-2015-207688Exarchou S., Lie E., Lindström U. et al. Mortality in ankylosing spondylitis: results from a nationwide population-based study. Ann. Rheum. Dis. 2016; 75: 1466–1472. doi: 10.1136/annrheumdis-2015-207688Kerola A. M., Kazemi A., Rollefstad S. et al. All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study. Rheumatology. 2022; 61 (12): 4656e66. doi: 10.1093/rheumatology/keac210Kerola A. M., Kazemi A., Rollefstad S. et al. All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study. Rheumatology. 2022; 61 (12): 4656e66. doi: 10.1093/rheumatology/keac210Turina M. C., Yeremenko N., van Gaalen F. et al. Serum inflammatory biomarkers fail to identify early axial spondyloarthritis: results from the SpondyloArthritis Caught Early (SPACE) cohort. RMD Open. 2017; 3: e000319. doi: 10.1136/rmdopen-2016-000319Turina M. C., Yeremenko N., van Gaalen F. et al. Serum inflammatory biomarkers fail to identify early axial spondyloarthritis: results from the SpondyloArthritis Caught Early (SPACE) cohort. RMD Open. 2017; 3: e000319. doi: 10.1136/rmdopen-2016-000319Skov L., Thomsen S. F., Kristensen L. E. et al. Cause-specific mortality in patients with psoriasis and psoriatic arthritis. Br. J. Dermatol. 2019; 180 (1): 100e7. doi: 10.1111/bjd.16919Skov L., Thomsen S. F., Kristensen L. E. et al. Cause-specific mortality in patients with psoriasis and psoriatic arthritis. Br. J. Dermatol. 2019; 180 (1): 100e7. doi: 10.1111/bjd.16919van der Heijde D., Wei J. C., Dougados M. et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018; 392: 2441–451. doi: 10.1016/S0140-6736(18)31946-9van der Heijde D., Wei J. C., Dougados M. et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018; 392: 2441–451. doi: 10.1016/S0140-6736(18)31946-9Баткаева Н. В., Коротаева Т. В., Баткаев Э. А. Структура кардиоваскулярной коморбидности у больных с тяжелыми формами псориаза: данные ретроспективного анализа госпитальной когорты. Научно-практическая ревматология. 2017; 55 (5): 493–499.Batkaeva N. V., Korotaeva T. V., Batkaev E. A. The pattern of cardiovascular comorbidity in patients with severe forms of psoriasis: Data of retrospective analysis of a hospital cohort. Rheumatology Science and Practice. 2017; 55 (5): 493–499. (In Russ.). doi: 10.14412/1995-4484-2017-493-499Derakhshan M. H., Goodson N. J., Packham J. C. et al. Increased risk of hypertension associated with spondyloarthritis disease duration: results from the ASAS-COMOSPA study. J. Rheumatol. 2019; 46 (7): 701–709. doi: 10.3899/jrheum.180538Derakhshan M. H., Goodson N. J., Packham J. C. et al. Increased risk of hypertension associated with spondyloarthritis disease duration: results from the ASAS-COMOSPA study. J. Rheumatol. 2019; 46 (7): 701–709. doi: 10.3899/jrheum.180538Liew J. W., Ward M. M., Reveille J. D. et al. Nonsteroidal antiinflammatory drug use and association with incident hypertension in ankylosing spondylitis. Arthritis Care Res. 2020; 72 (11): 1645e52. doi: 10.1002/acr.24070Liew J. W., Ward M. M., Reveille J. D. et al. Nonsteroidal antiinflammatory drug use and association with incident hypertension in ankylosing spondylitis. Arthritis Care Res. 2020; 72 (11): 1645e52. doi: 10.1002/acr.24070Tibuakuu M., Kamimura D., Kianoush S. et al. The association between cigarette smoking and inflammation: the Genetic Epidemiology Network of Arteriopathy (GENOA) study. PLoS One. 2017; 12: e0184914. doi: 10.1371/journal.pone.0184914Tibuakuu M., Kamimura D., Kianoush S. et al. The association between cigarette smoking and inflammation: the Genetic Epidemiology Network of Arteriopathy (GENOA) study. PLoS One. 2017; 12: e0184914. doi: 10.1371/journal.pone.0184914Gisondi P., Fostini A. C., Fossà I. et al. Psoriasis and the metabolic syndrome. Clin. Dermatol. 2018; 36 (1): 21–28. doi: 10.1016/j.clindermatol.2017.09.005Gisondi P., Fostini A. C., Fossà I. et al. Psoriasis and the metabolic syndrome. Clin. Dermatol. 2018; 36 (1): 21–28. doi: 10.1016/j.clindermatol.2017.09.005Wibetoe G., Ikdahl E., Rollefstad S. et al. Cardiovascular disease risk profiles in inflammatory joint disease entities. Arthritis Res. Ther. 2017; 19: 153. doi: 10.1186/s13075-017-1358-1Wibetoe G., Ikdahl E., Rollefstad S. et al. Cardiovascular disease risk profiles in inflammatory joint disease entities. Arthritis Res. Ther. 2017; 19: 153. doi: 10.1186/s13075-017-1358-1Gkolfinopoulou C., Stratikos E., Theofilatos D. et al. Impaired antiatherogenic functions of high-density lipoprotein in patients with ankylosing spondylitis. J. Rheumatol. 2015; 42: 1652–1660. doi: 10.3899/jrheum.141532Gkolfinopoulou C., Stratikos E., Theofilatos D. et al. Impaired antiatherogenic functions of high-density lipoprotein in patients with ankylosing spondylitis. J. Rheumatol. 2015; 42: 1652–1660. doi: 10.3899/jrheum.141532van der Heijde D., Ramiro S., Landewé R. et al. 2016 update of the ASAS-EULAR management recom-mendations for axial spondyloarthritis. Ann. Rheum. Dis. 2017; 76 (6): 978–991. doi: 10.1136/annrheumdis-2016-210770van der Heijde D., Ramiro S., Landewé R. et al. 2016 update of the ASAS-EULAR management recom-mendations for axial spondyloarthritis. Ann. Rheum. Dis. 2017; 76 (6): 978–991. doi: 10.1136/annrheumdis-2016-210770Genre F., Rueda-Gotor J., Quevedo-Abeledo J.C. et al. Insulin resistance in non-diabetes patients with spondyloarthritis. Scand. J. Rheumatol. 2020; 49 (6): 476–483. doi: 10.1080/03009742.2020.1751272Genre F., Rueda-Gotor J., Quevedo-Abeledo J.C. et al. Insulin resistance in non-diabetes patients with spondyloarthritis. Scand. J. Rheumatol. 2020; 49 (6): 476–483. doi: 10.1080/03009742.2020.1751272Kumthekar A., Ogdie A. Obesity and psoriatic arthritis : a narrative review. Rheumatol. Ther. 2020; 7 (3): 447e56. doi: 10.1007/s40744-020-00215-6Kumthekar A., Ogdie A. Obesity and psoriatic arthritis : a narrative review. Rheumatol. Ther. 2020; 7 (3): 447e56. doi: 10.1007/s40744-020-00215-6Bindesbøll C., Garrido-Cumbrera M., Bakland G. et al. Obesity increases disease activity of Norwegian patients with axial spondyloarthritis: results from the European map of axial spondyloarthritis survey. Curr. Rheumatol. Rep. 2020; 22(8): 43. doi: 10.1007/s11926-020-00917-4Bindesbøll C., Garrido-Cumbrera M., Bakland G. et al. Obesity increases disease activity of Norwegian patients with axial spondyloarthritis: results from the European map of axial spondyloarthritis survey. Curr. Rheumatol. Rep. 2020; 22(8): 43. doi: 10.1007/s11926-020-00917-4Liew J. W., Huang I. J., Louden D. N. et al. Association of body mass index on disease activity in axial spondyloarthritis : systematic review and meta-analysis. RMD Open. 2020; 6 (1): e001225. doi: 10.1136/rmdopen-2020–001225Liew J. W., Huang I. J., Louden D. N. et al. Association of body mass index on disease activity in axial spondyloarthritis : systematic review and meta-analysis. RMD Open. 2020; 6 (1): e001225. doi: 10.1136/rmdopen-2020–001225Ortolan A., Lorenzin M., Felicetti M. et al. Do obesity and overweight influence disease activity measures in axial spondyloarthritis? A systematic review and meta-analysis. Arthritis Care Res. 2021; 73 (12): 1815e25. doi: 10.1002/acr.24416Ortolan A., Lorenzin M., Felicetti M. et al. Do obesity and overweight influence disease activity measures in axial spondyloarthritis? A systematic review and meta-analysis. Arthritis Care Res. 2021; 73 (12): 1815e25. doi: 10.1002/acr.24416Walsh J. A., Wan M. T., Willinger C. et al. Measuring outcomes in psoriatic arthritis: comparing routine assessment of patient index data and psoriatic arthritis impact of disease. J. Rheumatol. 2020; 47 (10): 1496e505. doi: 10.3899/jrheum.190219Walsh J. A., Wan M. T., Willinger C. et al. Measuring outcomes in psoriatic arthritis: comparing routine assessment of patient index data and psoriatic arthritis impact of disease. J. Rheumatol. 2020; 47 (10): 1496e505. doi: 10.3899/jrheum.190219Garrido-Cumbrera M., Gálvez-Ruiz D., Delgado-Domínguez C.J. et al. Impact of axial spondyloarthritis on mental health in Europe: results from the EMAS study. RMD Open. 2021; 7 (3): e001769. doi: 10.1136/rmdopen-2021–001769Garrido-Cumbrera M., Gálvez-Ruiz D., Delgado-Domínguez C.J. et al. Impact of axial spondyloarthritis on mental health in Europe: results from the EMAS study. RMD Open. 2021; 7 (3): e001769. doi: 10.1136/rmdopen-2021–001769Zhao S. S., Radner H., Siebert S. et al. Comorbidity burden in axial spondyloarthritis: a cluster analysis. Rheumatology. 2019; 58 (10): 1746e54. doi: 10.1093/rheumatology/kez119Zhao S. S., Radner H., Siebert S. et al. Comorbidity burden in axial spondyloarthritis: a cluster analysis. Rheumatology. 2019; 58 (10): 1746e54. doi: 10.1093/rheumatology/kez119Zhao S. S., Miller N., Harrison N. et al. Systematic review of mental health comorbidities in psoriatic arthritis. Clin. Rheumatol. 2020; 39 (1): 217e25. doi: 10.1007/s10067-019-04734-8Zhao S. S., Miller N., Harrison N. et al. Systematic review of mental health comorbidities in psoriatic arthritis. Clin. Rheumatol. 2020; 39 (1): 217e25. doi: 10.1007/s10067-019-04734-8Zhao S. S., Jones G. T., Hughes D. M. et al. Depression and anxiety symptoms at TNF inhibitor initiation are associated with impaired treatment response in axial spondyloarthritis. Rheumatology. 2021; 60 (12): 5734e42. doi: 10.1093/rheumatology/keab242Zhao S. S., Jones G. T., Hughes D. M. et al. Depression and anxiety symptoms at TNF inhibitor initiation are associated with impaired treatment response in axial spondyloarthritis. Rheumatology. 2021; 60 (12): 5734e42. doi: 10.1093/rheumatology/keab242Cai M., Liu W., Wu Y. et al. The serum uric acid is longitudinally related to patients global assessment of disease activity in male patients with axial spondyloarthritis BMC Musculoskelet Disord. 2022; 23 (1): 717. doi: 10.1186/s12891-022-05657-3Cai M., Liu W., Wu Y. et al. The serum uric acid is longitudinally related to patients global assessment of disease activity in male patients with axial spondyloarthritis BMC Musculoskelet Disord. 2022; 23 (1): 717. doi: 10.1186/s12891-022-05657-3Sargın B., Gurer G., Boztaş G. T., Ozturk H. Association between serum uric acid and inflammation markers in ankylosing spondylitis patients treated with tumor necrosis factor-α or nonsteroidal anti-inflammatory drugs. Eur. Res. J. 2019; 5 (1): 104–108. doi: 10.18621/eurj.359504Sargın B., Gurer G., Boztaş G. T., Ozturk H. Association between serum uric acid and inflammation markers in ankylosing spondylitis patients treated with tumor necrosis factor-α or nonsteroidal anti-inflammatory drugs. Eur. Res. J. 2019; 5 (1): 104–108. doi: 10.18621/eurj.359504Lai Y., Zhang Y., Lei Z. et al. Association between serum uric acid concentration and radiographic axial spondylarthritis: a cross-sectional study of 202 patients. Chin. Med. J. 2023; 136: 1114–1116. doi: 10.1097/CM9.0000000000002148Lai Y., Zhang Y., Lei Z. et al. Association between serum uric acid concentration and radiographic axial spondylarthritis: a cross-sectional study of 202 patients. Chin. Med. J. 2023; 136: 1114–1116. doi: 10.1097/CM9.0000000000002148

The authors declare that there are no conflicts of interest present.